1. The administration of atomoxetine during alcohol deprivation induces a time-limited increase in alcohol consumption after relapse.
- Author
-
Alén F, Serrano A, Gorriti MÁ, Pavón FJ, Orio L, de Heras RG, Ramírez-López MT, Antón M, Pozo MÁ, and Rodríguez de Fonseca F
- Subjects
- Adrenergic Uptake Inhibitors pharmacology, Analysis of Variance, Animals, Atomoxetine Hydrochloride, Central Nervous System Depressants pharmacology, Conditioning, Operant drug effects, Disease Models, Animal, Locomotion drug effects, Male, Propylamines pharmacology, Rats, Rats, Wistar, Recurrence, Self Administration, Adrenergic Uptake Inhibitors therapeutic use, Alcohol Drinking drug therapy, Alcohol Drinking physiopathology, Central Nervous System Depressants administration & dosage, Ethanol administration & dosage, Propylamines therapeutic use
- Abstract
The administration of selective serotonin reuptake inhibitors (SSRIs) typically used as antidepressants increases alcohol consumption after an alcohol deprivation period in rats. However, the appearance of this effect after the treatment with selective noradrenaline reuptake inhibitors (SNRIs) has not been studied. In the present work we examined the effects of a 15-d treatment with the SNRI atomoxetine (1, 3 and 10 mg/kg, i.p.) in male rats trained to drink alcohol solutions in a 4-bottle choice test. The treatment with atomoxetine (10 mg/kg, i.p.) during an alcohol deprivation period increased alcohol consumption after relapse. This effect only lasted one week, disappearing thereafter. Treatment with atomoxetine did not cause a behavioral sensitized response to a challenge dose of amphetamine (1.5 mg/kg, i.p.), indicating the absence of a supersensitive dopaminergic transmission. This effect is markedly different from that of SSRI antidepressants that produced both long-lasting increases in alcohol consumption and behavioral sensitization. Clinical implications are discussed.
- Published
- 2014
- Full Text
- View/download PDF